165 related articles for article (PubMed ID: 7505345)
1. [Changes in coagulation and fibrinolytic factors observed during heparin-urokinase-pulse combined therapy for nephritis resistant to conventional treatment in children].
Koitabashi Y; Ikoma M; Shibawaka T; Yamaguchi Y; Mio H; Doi K; Meguro T; Yamada K
Nihon Jinzo Gakkai Shi; 1993 Oct; 35(10):1155-61. PubMed ID: 7505345
[TBL] [Abstract][Full Text] [Related]
2. Enhanced fibrinolytic activity during the course of hemodialysis.
Nakamura Y; Tomura S; Tachibana K; Chida Y; Marumo F
Clin Nephrol; 1992 Aug; 38(2):90-6. PubMed ID: 1387598
[TBL] [Abstract][Full Text] [Related]
3. [Combined use of heparin and urokinase in the patients with nephritis resistant to the conventional treatment and the significance of alpha 2-plasmin inhibitor in the therapy (author's transl)].
Koitabashi Y; Maruyama T; Ikoma M; Miyaji Y; Yamada K; Shimizu K
Rinsho Ketsueki; 1982 Mar; 23(3):309-18. PubMed ID: 7050462
[No Abstract] [Full Text] [Related]
4. [An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model].
Kawakami K; Takahashi A; Yoshimoto T
No To Shinkei; 1990 Feb; 42(2):193-201. PubMed ID: 2113401
[TBL] [Abstract][Full Text] [Related]
5. [Serial changes in hemostatic molecular markers after urokinase therapy of acute myocardial infarction].
Goto S; Kawai Y; Watanabe K; Hori S; Abe S; Handa S; Ikeda Y
Kokyu To Junkan; 1992 Jan; 40(1):89-95. PubMed ID: 1532665
[TBL] [Abstract][Full Text] [Related]
6. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
[TBL] [Abstract][Full Text] [Related]
7. [Activation of fibrynolysis in children with chronic B or C hepatitis].
Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
[TBL] [Abstract][Full Text] [Related]
8. Effects of direct percutaneous transluminal coronary angioplasty treatment of acute myocardial infarction on plasma levels of haemostatic and fibrinolytic factors.
Saito M; Nakabayashi T; Iuchi K; Ishikawa T; Kaseno K; Yoshida T; Asakura H; Matsuda T
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):801-4. PubMed ID: 7507363
[TBL] [Abstract][Full Text] [Related]
9. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
Vaziri ND; Gonzales EC; Shayestehfar B; Barton CH
J Lab Clin Med; 1994 Jul; 124(1):118-24. PubMed ID: 7518491
[TBL] [Abstract][Full Text] [Related]
10. Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
Theiss W; Asbeck F; Kriessmann A; Trübestein G; Knoch K; de Swart CA; Marbert GA; van de Loo JC
Thromb Haemost; 1983 Oct; 50(3):664-8. PubMed ID: 6196852
[TBL] [Abstract][Full Text] [Related]
11. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma.
Sørensen JV
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044
[TBL] [Abstract][Full Text] [Related]
12. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
13. The fibrinolytic system in neoplasia.
Bell WR
Semin Thromb Hemost; 1996; 22(6):459-78. PubMed ID: 9122711
[TBL] [Abstract][Full Text] [Related]
14. [The changes of alpha 2-plasmin inhibitor, and notably urokinase activities in blood measured by synthetic chromogenic substrates S-2444 after urokinase administration].
Itoh Y; Tsuji K; Tanaka N; Yamada M; Nakanishi M; Ishihara M; Kobayashi M
Nihon Sanka Fujinka Gakkai Zasshi; 1983 Jan; 35(1):68-76. PubMed ID: 6338134
[TBL] [Abstract][Full Text] [Related]
15. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
17. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
18. Novel distribution pattern of fibrinolytic components in rabbit tissues extract: a preliminary study.
Lu XG; Wu XG; Xu XH; Gong XB; Zhou X; Xu GB; Zhu L; Zhao XY
J Zhejiang Univ Sci B; 2007 Aug; 8(8):570-4. PubMed ID: 17657859
[TBL] [Abstract][Full Text] [Related]
19. Modifications in coagulation parameters induced by treatment associating urokinase (2000 u CTA/kg/h) with heparin.
Juhan I; Calas MF; Buonocore M; Mathieu P; Isnard G; Cazenave B; Serradimigni A
Thromb Haemost; 1979 Oct; 42(3):945-54. PubMed ID: 315625
[No Abstract] [Full Text] [Related]
20. [Levels of tissue-type plasminogen activator and plasminogen activator inhibitor 1 in disseminated intravascular coagulation syndrome].
Fukao H; Yamamoto K; Matsuo O
Rinsho Byori; 1991 Jul; 39(7):720-6. PubMed ID: 1920864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
